TECX
Tectonic Therapeutic, Inc. · Healthcare
29.98
1.77%(-0.54)
Prev. Close34.05
13.58%(+4.07)
Pre-marketLast Updated: — ET
52W L: $13.7052W H: $36.03
$32.40
CHG-3.36 (-9.40%)
H$35.96
L$28.25
VOL4.3M
TECX (1h)
TECX NEWS
defenseworld.net
9h ago
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $81.50 Consensus Price Target from Analysts
Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven brokerages that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating
defenseworld.net
1d ago
Aberdeen Group plc Acquires 785,648 Shares of Tectonic Therapeutic, Inc. $TECX
Aberdeen Group plc boosted its holdings in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 220.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,141,824 shares of the company's stock after acquiring an additional 785,648 shares during
defenseworld.net
Mar 15
Tectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLC
Ally Bridge Group NY LLC lowered its stake in shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) by 15.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 138,595 shares of the company's stock after selling 25,088 shares during the quarter. Tectonic Therapeutic accounts
defenseworld.net
Mar 10
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on
seekingalpha.com
Mar 6
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
globenewswire.com
Feb 26
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an overview of recent business highlights.